AstraZeneca's Imfinzi gets FDA approval for lung cancer treatment
AstraZeneca
10,436.00p
12:54 24/12/24
0.13%
14.00p
AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
FTSE 100
8,136.99
12:59 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
The approval by the Food and Drug Administration (FDA) was based on the results from the Poseidon Phase 3 trial.
Patients treated with a limited course of five cycles of Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options.
Reporting by Frank Prenesti for Sharecast.com